CSPC Pharmaceutical Group Ltd CVG
News
-
Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
-
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC Pharmaceuticals — 2nd Update
-
AstraZeneca Strikes Obesity Multibillion-Dollar Deal With China's CSPC Pharmaceuticals — Update
-
CSPC Pharma Shares Drop on Possible Profit-Taking After AstraZeneca Deal
-
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
-
Chinese Pharma Group CSPC's Unit Proceeds With Hong Kong Offering
-
Chinese Pharma Stocks Fall on Potential U.S. Restrictions on Drugs
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 11.41B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 36.16
- Price/Sales
- 4.30
- Dividend Yield (Trailing)
- 0.99%
- Dividend Yield (Forward)
- 1.50%
- Dividend Payment Schedule
- Jul, Nov
- Total Yield
- 0.99%
Company Profile
CSPC Pharmaceutical Group LTD is engaged in the manufacture and sale of pharmaceutical products. The group's segments include: Finished drugs, consisting research and development, manufacture and sale of pharmaceutical products and license fee income; Bulk products, that manufacture and sale of vitamin C, and antibiotic products in bulk powder form; and Functional food and others, that manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. It derives maximum revenue from Finished Products segments. Geographically, the company operates in Chinese Mainland, which Chinese Mainland generates maximum revenue; Other Asian regions; Europe; North America; and Others.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 18,626
- Website
- https://www.cspc.com.hk
Valuation
|
Metric
|
CVG
|
|---|---|
Price/Earnings (Normalized) | 36.16 |
Price/Book Value | 5.30 |
Price/Sales | 4.30 |
Price/Cash Flow | 24.93 |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CVG
|
|---|---|
Quick Ratio | 1.90 |
Current Ratio | 2.14 |
Interest Coverage | 299.30 |
Quick Ratio
CVG
Profitability
|
Metric
|
CVG
|
|---|---|
Return on Assets (Normalized) | 14.89% |
Return on Equity (Normalized) | 21.30% |
Return on Invested Capital (Normalized) | 19.64% |
Return on Assets
CVG
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|VgmKPbd | LOCK|#h | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|%GRmVZ | LOCK|m< | $599B | |||
| AbbVie Inc
ABBV
| LOCK|VQ!%xS | LOCK|vw | $485B | |||
| Merck & Co Inc
MRK
| LOCK|!^>>!Qf | LOCK|!&@ | $350B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|#Vv^N>q! | LOCK|cN | $345B | |||
| Novartis AG ADR
NVS
| LOCK|^fk$PyJ | LOCK|^xQ | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|kxXTJ!!% | LOCK|yS | $244B | |||
| Amgen Inc
AMGN
| LOCK|Grx>ND%d | LOCK|Fw> | $223B | |||
| Gilead Sciences Inc
GILD
| LOCK|?pM!s% | LOCK|Gh& | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|^N@Y?^d | LOCK|?# | $169B |
United States